MedImmune for sale
Executive Summary
The biotechnology firm announces April 12 that it is exploring a possible sale. MedImmune has a market capitalization of over $10 billion and markets the influenza vaccine FluMist, the respiratory syncytial virus treatment Synagis (palivizumab) and the cytoprotective agent Ethyol (amifostine). A BLA for the Synagis follow-on Numax is planned for this year. The firm already has relationships with Merck and GlaxoSmithKline, which use the firm's "virus-like particle technology" in the production of HPV vaccines Gardasil and Cervarix. Pfizer has also expressed an interest in significantly boosting its biologics portfolio via acquisition...
You may also be interested in...
Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows
AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.